CRNX Crinetics Pharmaceuticals, Inc. Stock Quote

CRNX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.45	Insider Own	0.20%	Shs Outstand	32.97M	Perf Week	-1.99%
Market Cap	650.96M	Forward P/E	-	EPS next Y	-2.92	Insider Trans	397.24%	Shs Float	27.82M	Perf Month	1.39%
Income	-73.80M	PEG	-	EPS next Q	-0.65	Inst Own	84.20%	Short Float	5.43%	Perf Quarter	13.19%
Sales	0.07M	P/S	9168.51	EPS this Y	-16.20%	Inst Trans	0.87%	Short Ratio	10.65	Perf Half Y	3.46%
Book/sh	5.12	P/B	3.27	EPS next Y	-12.30%	ROA	-40.70%	Target Price	-	Perf Year	8.07%
Cash/sh	4.39	P/C	3.81	EPS next 5Y	-	ROE	-44.20%	52W Range	11.61 - 23.70	Perf YTD	18.57%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-29.41%	Beta	-
Dividend %	-	Quick Ratio	16.90	Sales past 5Y	-	Gross Margin	-	52W Low	44.10%	ATR	1.16
Employees	93	Current Ratio	16.90	Sales Q/Q	-100.00%	Oper. Margin	-	RSI (14)	53.06	Volatility	7.14% 6.79%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-9.30%	Profit Margin	-	Rel Volume	0.98	Prev Close	17.32
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 30 AMC	Payout	-	Avg Volume	141.71K	Price	16.73
Recom	2.00	SMA20	2.50%	SMA50	3.82%	SMA200	11.55%	Volume	139,501	Change	-3.41%

Dec-23-19

Initiated

ROTH Capital

Buy

$37

Feb-14-19

Initiated

H.C. Wainwright

Buy

$35

Aug-13-18

Initiated

Piper Jaffray

Overweight

$40

Aug-13-18

Initiated

Leerink Partners

Outperform

$43

Aug-13-18

Initiated

JP Morgan

Neutral

$29

Apr-12-21 04:05PM	Crinetics Pharmaceuticals Announces Closing of Common Stock Offering GlobeNewswire
02:32AM	What Type Of Shareholders Own The Most Number of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares? Simply Wall St.
Apr-07-21 06:31PM	Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Mar-30-21 04:05PM	Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
02:30PM	Crinetics Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-24-21 07:10AM	Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
Mar-22-21 07:10AM	Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021 GlobeNewswire
Mar-12-21 07:10AM	Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs GlobeNewswire
Feb-04-21 07:10AM	Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushings Disease (CRN04894) Advances into Phase 1 Study GlobeNewswire
Feb-03-21 07:10AM	Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study GlobeNewswire
Jan-06-21 07:05AM	Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire +6.77%
Dec-27-20 01:37AM	Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation Simply Wall St.
Dec-15-20 11:26PM	Is CRNX A Good Stock To Buy Now? Insider Monkey
Nov-23-20 07:30AM	Crinetics Pharmaceuticals to Participate in December Investor Conferences GlobeNewswire -5.05%
Nov-16-20 07:30AM	Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology GlobeNewswire +5.51%
Nov-13-20 07:30AM	Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly GlobeNewswire
Nov-09-20 11:04AM	Should You Buy Crinetics Pharmaceuticals (CRNX) Ahead of Earnings? Zacks
Nov-06-20 08:31AM	Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire -6.01%
Oct-26-20 07:02AM	Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint GlobeNewswire -10.47%
Oct-14-20 10:25AM	Hedge Funds Are Piling Into Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey
Sep-21-20 07:30AM	Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism GlobeNewswire
Sep-04-20 07:30AM	Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology GlobeNewswire
Sep-03-20 05:56PM	Crinetics Pharmaceuticals to Participate in September Investor Conferences GlobeNewswire -8.05%
07:30AM	Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors GlobeNewswire
Aug-07-20 07:30AM	Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +8.83%
Jul-08-20 04:05PM	Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly GlobeNewswire
Jul-05-20 05:29PM	Should You Avoid Crinetics Pharmaceuticals, Inc. (CRNX)? Insider Monkey
Jun-30-20 07:02AM	Analysts' Revenue Estimates For Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Are Surging Higher Simply Wall St.
Jun-19-20 10:05AM	Crinetics Pharmaceuticals, Inc. (CRNX) Shares March Higher, Can It Continue? Zacks +16.32%
Jun-11-20 07:30AM	Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine GlobeNewswire -8.89%
May-27-20 07:30AM	Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human Resources GlobeNewswire
May-14-20 08:51AM	Is Crinetics Pharmaceuticals (CRNX) Stock a Solid Choice Right Now? Zacks
May-08-20 09:01AM	Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +5.01%
Apr-17-20 04:05PM	Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
12:00PM	Crinetics Pharmaceuticals, Inc. (CRNX) Upgraded to Buy: Here's What You Should Know Zacks
Apr-15-20 12:22AM	Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Apr-14-20 04:05PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire +5.33%
Apr-07-20 07:55AM	The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation Benzinga -10.93%
Apr-06-20 04:30PM	Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update GlobeNewswire +10.99%
Mar-09-20 04:10PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Mar-04-20 12:30PM	Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-19-20 07:30AM	Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-28-20 07:11AM	Those Who Purchased Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares A Year Ago Have A 11% Loss To Show For It Simply Wall St.
Jan-08-20 07:30AM	Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire +5.61%
Dec-14-19 08:42PM	Hedge Funds Have Never Been This Bullish On Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey
Nov-26-19 04:05PM	Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference GlobeNewswire
Nov-12-19 06:15PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:04PM	Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-05-19 10:31AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q3 Earnings Expected to Decline Zacks
Oct-30-19 10:57AM	Hedge Funds Have Never Been This Bullish On Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey
Oct-28-19 11:31AM	We're Not Very Worried About Crinetics Pharmaceuticals's (NASDAQ:CRNX) Cash Burn Rate Simply Wall St.
Sep-25-19 07:30AM	Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference GlobeNewswire +6.32%
Sep-12-19 08:40AM	What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell? Zacks
Sep-03-19 04:05PM	Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-13-19 06:15PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:14PM	Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-30-19 02:35PM	If You Had Bought Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock A Year Ago, You'd Be Sitting On A 14% Loss, Today Simply Wall St.
Jul-29-19 07:30AM	Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism GlobeNewswire -5.72%
Jul-16-19 09:05AM	Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors GlobeNewswire
May-21-19 07:30AM	Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors GlobeNewswire
May-13-19 04:11PM	Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-07-19 12:54PM	Heres What Hedge Funds Think About Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey -5.67%
Mar-19-19 07:30AM	Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly GlobeNewswire
Mar-18-19 07:30AM	Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning GlobeNewswire
Mar-14-19 04:27PM	Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019 GlobeNewswire
Mar-13-19 04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-21-19 07:30AM	Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference GlobeNewswire -6.51%
Jan-16-19 10:16AM	Top 5 Small-Cap Winners And Losers, Week Of Jan. 7 Benzinga
Jan-08-19 12:50PM	At biotech's big event, a chance for execs to shape LGBTQ diversity on boards American City Business Journals
Jan-02-19 04:05PM	Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Nov-21-18 08:20AM	New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +9.88%
Nov-20-18 07:30AM	Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference GlobeNewswire
Nov-13-18 04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire +10.85%
Sep-26-18 04:05PM	Crinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Aug-30-18 04:07PM	Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-20-18 04:05PM	Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-19-18 08:00AM	Todays Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals ACCESSWIRE -7.55%
Jul-18-18 11:37AM	Crinetics Pharmaceuticals stock surges 24% in trading debut MarketWatch
07:27AM	Crinetics Pharmaceuticals prices IPO at $17 a share MarketWatch
Jul-17-18 06:55PM	Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 08	Buy	16.44	304,136	4,999,996	3,963,517	Apr 09 09:00 AM
Struthers Richard Scott	President & CEO	Dec 03	Buy	13.10	4,000	52,400	4,000	Dec 04 04:59 PM
Struthers Richard Scott	President & CEO	Dec 02	Buy	12.60	1,000	12,600	1,000	Dec 04 04:59 PM
Struthers Richard Scott	President & CEO	Jul 16	Sale	14.46	17,500	253,108	890,805	Jul 17 05:05 PM
Struthers Richard Scott	President & CEO	Jul 15	Sale	15.30	17,500	267,722	908,305	Jul 17 05:05 PM
WIERENGA WENDALL	Director	Apr 28	Option Exercise	0.73	25,329	18,490	99,846	Apr 29 05:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience